Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ignyta buys rights to taladegib oncology program from Eli Lilly
Under the deal, Lilly will receive an upfront payment of $2m in cash, 1.2 million shares of Ignyta common stock, up to $38m in milestones and royalties on
Under the deal, Lilly will receive an upfront payment of $2m in cash, 1.2 million shares of Ignyta common stock, up to $38m in milestones and royalties on
US-based ZS Pharma develops and commercializes highly selective, non-absorbed drugs for the treatment of renal, cardiovascular, liver and metabolic disorders. The company employs about 200 people across three
Sotagliflozin (LX4211) is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for diabetes patients.
JKB-122 is a TLR4 (Toll-like Receptor 4) antagonist on patients with AIH who are refractory to or intolerant to the existing standard of care (SOC). Duke Clinical Research
Under the PAZOFOS randomized, controlled clinical study, OxiGENE plans to enroll up to 128 patients at up to ten sites in the UK. It includes a phase 1b
The company plans to extend the existing indication for Opdivo to include the treatment of adult patients with advanced RCC after prior therapy. Validation confirms that the application
Genvoya, a combination tablet approved as a complete regimen, is designed to treat earlier untreated patients weighing about 35 kilograms. It features elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
RPL554 is the company’s lead drug, which is being evaluated in asthma and chronic obstructive pulmonary disease (COPD). The drug is a novel inhaled PDE3/PDE4 inhibitor with anti-inflammatory
Novira is focused on the discovery and development of therapies to treat chronic hepatitis B (CHB) infection. The company’s novel antiviral drug candidates have the potential to address
Sanofi will pay Hanmi €400m up front and possibly a further €3.5bn in development, registration and sales milestones, in addition to double digit royalties on net sales. In